Ishita Chatterjee

Oligomerix, Inc. develops novel therapeutics and diagnostic assays for alzheimer diseases. It is a biopharmaceutical company focused on the discovery and development of small molecule inhibitors, immunotherapeutic approaches and biomarkers targeting tau oligomers. The firm's platform is based on small neurotoxic aggregates of proteins such as tau oligomers, an important target for AD and other tauopathies characterized by the progressive accumulation of tau aggregates. The company was founded by James G. Moe, Eliot J. Davidowitz, Ishita Chatterjee and Pedro M. Rojas in 2006 and is headquartered in New York, NY.

ARMGO Pharma, Inc. discovers and develops novel small-molecule therapeutics. Its product include Rycal Science is an inspiring new direction in therapy for the leading causes of morbidity and mortality; Rycals are small-molecule therapeutics developed in the laboratory. The company was founded in 2004 and is headquartered in New York, NY.